Islet Sciences buys Diakine in diabetes merger
This article was originally published in Scrip
Executive Summary
Islet Sciences, which is developing products for insulin-dependent diabetes around its islet cell transplantation technology, is to acquire DiaKine Therapeutics in an all-share deal. DiaKine is developing novel immune modulators to treat diabetes and related conditions.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi’s New Loan Offers Win-Win Model For Pharma And Society
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Need a specific report? 1000+ reports available
Buy Reports